People
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The company’s lead drug candidate, Repotrectinib, is currently in Phase I/II clinical studies to target non-small cell lung cancer (NSCLC) in patients with a ROS1 or NTRK metastatic mutation.
AstraZeneca Chief Executive Officer Pascal Soriot is seeing a significant return on the fruits of his company’s labor in 2020. Soriot’s annual compensation jumped a bit from the previous year to $21.4 million.
Biotech investor Neil Woodford is poised for a comeback after a fall from grace two years ago.
A new biotech hotspot could be on the horizon in Oregon thanks to a $500 million gift to the University of Oregon from Nike co-founder Phil Knight, an alumnus of the university.
Josh Smiley’s termination from Eli Lilly for inappropriate communications with employees will cost more than a blow to his reputation.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The choice for the new FDA commissioner will tell the public about the Biden administration’s battle plan with regards to handling the global pandemic.
BigHat is a Bay-area startup that’s reimagining antibody development with the help of AI and ML (machine learning) technologies through data-driven discovery.
Anat Ashkenazi was tapped to take over as chief financial officer of Eli Lilly following the abrupt resignation of Josh Smiley, who departed the company following allegations of an inappropriate relationship with an employee.
PRESS RELEASES